title: Emerging therapeutic targets and strategies in Crohn's disease.
abstract: Crohn's disease (CD) is an immune-mediated inflammatory bowel disease, in which inflammation is driven by a complex interaction between the microbiota, immune cells, genes and mediators. New mechanisms of action and several cytokines have been identified as factors involved in the inflammatory process in CD, and many new molecules have been developed to treat this complex disease. New agents have been developed that target leukocyte trafficking, block or adhesion molecules for example, as well as the development of antibodies against classic inflammatory cytokines or therapies directed against IL-12/23 and Janus kinases. The development of selective mechanisms of action and targeting of different cytokines or inflammatory mediators for each patient presents the biggest challenge for the future in CD therapy. Such agents are currently at different phases of development. We aim to review the current literature data on a targeted approach in CD, which could be promising alternative approach for CD patients in the near future.
authors.affiliation: a IBD Center, Department of Gastroenterology , Humanitas Research Hospital , Rozzano , Milan , Italy.|b Department of Gastroenterology , University Study of Milan , Milan , Italy.
authors.forename: Federica
authors.initials: F
authors.lastname: Furfaro
authors.affiliation: a IBD Center, Department of Gastroenterology , Humanitas Research Hospital , Rozzano , Milan , Italy.
authors.forename: Gionata
authors.initials: G
authors.lastname: Fiorino
authors.affiliation: a IBD Center, Department of Gastroenterology , Humanitas Research Hospital , Rozzano , Milan , Italy.
authors.forename: Mariangela
authors.initials: M
authors.lastname: Allocca
authors.affiliation: a IBD Center, Department of Gastroenterology , Humanitas Research Hospital , Rozzano , Milan , Italy.
authors.forename: Daniela
authors.initials: D
authors.lastname: Gilardi
authors.affiliation: a IBD Center, Department of Gastroenterology , Humanitas Research Hospital , Rozzano , Milan , Italy.
authors.forename: Silvio
authors.initials: S
authors.lastname: Danese
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors* / Q000276:immunology; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors* / Q000276:immunology; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D058990:Molecular Targeted Therapy / Q000009:adverse effects; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D015815:Cell Adhesion Molecules; D005765:Gastrointestinal Agents; D018836:Inflammation Mediators
keywords: Crohn’s disease; anti-adhesion molecules; anti-cytokine; biologics; small molecules